MedTrace Logo

Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder

NCT03102918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-25

Study results available
· View outcomes & findings →

Summary

Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance, and cigarette use.

Conditions

  • Cannabis Use Disorder

Interventions

DRUG

Cannabidiol

Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.

DRUG

Placebo

Participants will receive placebo over a 6-week treatment period.

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-20
Primary Completion
2017-08-30
Completion
2017-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03102918 on ClinicalTrials.gov